Palisade Bio launches new corporate branding

Palisade Bio announced the launch of its new corporate branding and website, palisadebio.com and reiterated its commitment to stakeholders by advancing its lead product candidate, PALI-2108. The Company’s lead program, PALI-2108, is a microbiota-activated PDE4 inhibitor prodrug in development for the treatment of moderate-to-severe ulcerative colitis. Ulcerative colitis poses significant challenges for patients who need therapies that provide effective remission rates, that are non-immunosuppressive and that have improved safety profiles. Once clinical trials begin, the Company anticipates using advanced machine learning to identify patients with elevated PDE4 activity to enhance the responder population using PALI-2108 to target ulcerative colitis. By pinpointing key markers of colitis through RNA sequencing and meta-analysis, the Company will be able to identify top PDE4-effector genes, potentially enabling Palisade to predict patient responses to PDE4 inhibitors and hopefully ensure targeted, effective treatment. Additionally, the Company’s platform technology provides the opportunity to expand its pipeline across immune, inflammatory and fibrotic disease, including its PALI-1908 program in preclinical development for fibro stenotic Crohn’s Disease, which shares multiple synergies with the lead PALI-2108 program. In addition to the launch of its new website, the Company has released its latest corporate presentation, now available in the Investors section of the Company’s website.